426
Participants
Start Date
September 4, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
AR-17043 Ophthalmic Solution
Investigational monotherapy supplied in three concentration levels: low, medium, high
PG043 Ophthalmic Solution
Investigational fixed dose combination supplied in two concentration levels: low and high
Latanoprost 0.005% Ophthalmic Solution
Marketed monotherapy
Netarsudil 0.02% Ophthalmic Solution
Marketed monotherapy
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
Marketed fixed dose combination
AR-17043 Vehicle
Placebo comparator
Rochester Ophthalmological Group, Rochester
Scott & Christie and Associates, PC, Cranberry Township
Piedmont Eye Center, Lynchburg
James D. Branch Ophthalmology, Winston-Salem
Coastal Research Associates, Roswell
University Eye Specialists, Maryville
Total Eye Care PA, Memphis
Eye Center of Northern Colorado, PC, Fort Collins
United Medical Research Institute, Inglewood
Eye Research Foundation, Newport Beach
Orange County Ophthalmology Medical Group, Garden Grove
North Bay Eye Associates, Petaluma
Lead Sponsor
Alcon Research
INDUSTRY